Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185470 | 0.90 | NPC1 (0.55) | RAB9ANPC1ALDH1A1GLAL3MBTL1 | |
| SCHEMBL16527729 | 0.89 | HTT (0.51) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL16527728 | 0.89 | HTT (0.51) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL10184298 | 0.84 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MAPTLMNADGAT1 | |
| SCHEMBL10184848 | 0.83 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2MAPTLMNAPOLB | |
| SCHEMBL10186109 | 0.83 | HDAC3 (0.47) | RAB9AALDH1A1SMN1; SMN2DGAT1 | |
| SCHEMBL10184275 | 0.81 | HPGD (0.54) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL16527590 | 0.80 | DGAT1 (0.51) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL16527591 | 0.80 | DGAT1 (0.51) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL10184835 | 0.80 | HPGD (0.44) | ALDH1A1L3MBTL1SMN1; SMN2MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | RAB9A 1660/4885NPC1 201/4885ALDH1A1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.